Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline.


Journal

Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351

Informations de publication

Date de publication:
03 2021
Historique:
pubmed: 10 11 2020
medline: 23 3 2021
entrez: 9 11 2020
Statut: ppublish

Résumé

The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2020 for the management of patients with diabetes and chronic kidney disease (CKD). The KDIGO Work Group (WG) was tasked with developing the guideline for diabetes management in CKD. It defined the scope of the guideline, gathered evidence, determined systematic review topics, and graded evidence that had been summarized by an evidence review team. The English-language literature searches, which were initially done through October 2018, were updated in February 2020. The WG used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of the recommendations. Expert judgment was used to develop consensus practice points supplementary to the evidence-based graded recommendations. The guideline document underwent open public review. Comments from various stakeholders, subject matter experts, and industry and national organizations were considered before the document was finalized. The guideline includes 12 recommendations and 48 practice points for clinicians caring for patients with diabetes and CKD. This synopsis focuses on the key recommendations pertinent to the following issues: comprehensive care needs, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and educational and integrated care approaches.

Identifiants

pubmed: 33166222
doi: 10.7326/M20-5938
doi:

Types de publication

Journal Article Practice Guideline Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

385-394

Commentaires et corrections

Type : CommentIn

Auteurs

Sankar D Navaneethan (SD)

Section of Nephrology and Institute of Clinical and Translational Research, Baylor College of Medicine, and Michael E. DeBakey VA Medical Center, Houston, Texas (S.D.N.).

Sophia Zoungas (S)

Monash University, School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia (S.Z.).

M Luiza Caramori (ML)

University of Minnesota, Minneapolis, Minnesota (M.L.C.).

Juliana C N Chan (JCN)

Hong Kong Institute of Diabetes and Obesity and Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Hong Kong, China (J.C.C.).

Hiddo J L Heerspink (HJL)

University of Groningen and University Medical Center, Groningen, the Netherlands (H.J.H.).

Clint Hurst (C)

Houston, Texas (C.H.).

Adrian Liew (A)

Mount Elizabeth Novena Hospital, Singapore (A.L.).

Erin D Michos (ED)

Johns Hopkins University School of Medicine, Baltimore, Maryland (E.D.M.).

Wasiu A Olowu (WA)

Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun, Nigeria (W.A.O.).

Tami Sadusky (T)

Seattle, Washington (T.S.).

Nikhil Tandon (N)

All India Institute of Medical Sciences, New Delhi, India (N.T.).

Katherine R Tuttle (KR)

University of Washington, Spokane, Washington (K.R.T.).

Christoph Wanner (C)

University Hospital of Würzburg, Würzburg, Germany (C.W.).

Katy G Wilkens (KG)

Northwest Kidney Centers, Seattle, Washington (K.G.W.).

Lyubov Lytvyn (L)

MAGIC Evidence Ecosystem Foundation, McMaster University, Hamilton, Ontario, Canada (L.L.).

Jonathan C Craig (JC)

College of Medicine and Public Health, Flinders University, and Cochrane Kidney and Transplant, Adelaide, Australia (J.C.C.).

David J Tunnicliffe (DJ)

School of Public Health, The University of Sydney, and Cochrane Kidney and Transplant, Sydney, Australia (D.J.T., M.H.).

Martin Howell (M)

School of Public Health, The University of Sydney, and Cochrane Kidney and Transplant, Sydney, Australia (D.J.T., M.H.).

Marcello Tonelli (M)

University of Calgary, Calgary, Alberta, Canada (M.T.).

Michael Cheung (M)

KDIGO, Brussels, Belgium (M.C., A.E.).

Amy Earley (A)

KDIGO, Brussels, Belgium (M.C., A.E.).

Peter Rossing (P)

Steno Diabetes Center and University of Copenhagen, Copenhagen, Denmark (P.R.).

Ian H de Boer (IH)

University of Washington, Kidney Research Institute, Seattle, Washington (I.H.D.).

Kamlesh Khunti (K)

Diabetes Research Centre, University of Leicester, and Leicester General Hospital, Leicester, United Kingdom (K.K.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH